Get access to our best features

Get access to our best features

Pfizer's hemophilia B gene therapy succeeds in late-stage study

Summary by Ground News
Pfizer's investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial. The trial involved adults males with a moderately severe to severe form of the disease. Pfizer plans to disclose additional key data from the study at a scientific conference in early 2023.
Published 5 months ago

News Articles

More
Filters
All
Left
Center
Right

Similar News Topics

Show All
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

50% of the sources are Center
The Hindu
Bloomberg
Channel News Asia
Irish Times
STAT
Seeking Alpha
L 33%
C 50%
R 17%
See less detail